162 related articles for article (PubMed ID: 38358804)
21. Macrophage cell membrane infused biomimetic liposomes for glioblastoma targeted therapy.
Mendanha D; Vieira de Castro J; Casanova MR; Gimondi S; Ferreira H; Neves NM
Nanomedicine; 2023 Apr; 49():102663. PubMed ID: 36773669
[TBL] [Abstract][Full Text] [Related]
22. Engineered Macrophage-Membrane-Coated Nanoparticles with Enhanced PD-1 Expression Induce Immunomodulation for a Synergistic and Targeted Antiglioblastoma Activity.
Yin T; Fan Q; Hu F; Ma X; Yin Y; Wang B; Kuang L; Hu X; Xu B; Wang Y
Nano Lett; 2022 Aug; 22(16):6606-6614. PubMed ID: 35948420
[TBL] [Abstract][Full Text] [Related]
23. Synchronous Disintegration of Ferroptosis Defense Axis via Engineered Exosome-Conjugated Magnetic Nanoparticles for Glioblastoma Therapy.
Li B; Chen X; Qiu W; Zhao R; Duan J; Zhang S; Pan Z; Zhao S; Guo Q; Qi Y; Wang W; Deng L; Ni S; Sang Y; Xue H; Liu H; Li G
Adv Sci (Weinh); 2022 Jun; 9(17):e2105451. PubMed ID: 35508804
[TBL] [Abstract][Full Text] [Related]
24. CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy.
Chang Y; Cai X; Syahirah R; Yao Y; Xu Y; Jin G; Bhute VJ; Torregrosa-Allen S; Elzey BD; Won YY; Deng Q; Lian XL; Wang X; Eniola-Adefeso O; Bao X
Nat Commun; 2023 Apr; 14(1):2266. PubMed ID: 37080958
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of tumor progression and M2 microglial polarization by extracellular vesicle-mediated microRNA-124 in a 3D microfluidic glioblastoma microenvironment.
Hong S; You JY; Paek K; Park J; Kang SJ; Han EH; Choi N; Chung S; Rhee WJ; Kim JA
Theranostics; 2021; 11(19):9687-9704. PubMed ID: 34646393
[No Abstract] [Full Text] [Related]
26. Small Molecule Immunomodulators as Next-Generation Therapeutics for Glioblastoma.
Abdel-Rahman SA; Gabr M
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275876
[TBL] [Abstract][Full Text] [Related]
27. Recruiting T-Cells toward the Brain for Enhanced Glioblastoma Immunotherapeutic Efficacy by Co-Delivery of Cytokines and Immune Checkpoint Antibodies with Macrophage-Membrane-Camouflaged Nanovesicles.
Xu X; Zhang Z; Du J; Xue Y; Chen X; Zhang J; Yang X; Chang D; Xie J; Ju S
Adv Mater; 2023 Jun; 35(25):e2209785. PubMed ID: 37101060
[TBL] [Abstract][Full Text] [Related]
28. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
Wang D; Wang C; Wang L; Chen Y
Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
[TBL] [Abstract][Full Text] [Related]
29. Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities.
Wang G; Zhong K; Wang Z; Zhang Z; Tang X; Tong A; Zhou L
Front Immunol; 2022; 13():964898. PubMed ID: 35967394
[TBL] [Abstract][Full Text] [Related]
30. Brain-targeted antigen-generating nanoparticles improve glioblastoma prognosis.
Wang W; Zhang M; Zhang Q; Mohammadniaei M; Shen J; Sun Y
J Control Release; 2022 Dec; 352():399-410. PubMed ID: 36309097
[TBL] [Abstract][Full Text] [Related]
31. Advances in Nanotechnology-Based Immunotherapy for Glioblastoma.
Tang L; Zhang M; Liu C
Front Immunol; 2022; 13():882257. PubMed ID: 35651605
[TBL] [Abstract][Full Text] [Related]
32. Rapamycin and hydroxychloroquine combination alters macrophage polarization and sensitizes glioblastoma to immune checkpoint inhibitors.
Hsu SPC; Chen YC; Chiang HC; Huang YC; Huang CC; Wang HE; Wang YS; Chi KH
J Neurooncol; 2020 Feb; 146(3):417-426. PubMed ID: 32020472
[TBL] [Abstract][Full Text] [Related]
33. An miR-340-5p-macrophage feedback loop modulates the progression and tumor microenvironment of glioblastoma multiforme.
Liu Y; Li X; Zhang Y; Wang H; Rong X; Peng J; He L; Peng Y
Oncogene; 2019 Dec; 38(49):7399-7415. PubMed ID: 31427735
[TBL] [Abstract][Full Text] [Related]
34. Upregulation of Cathepsin X in Glioblastoma: Interplay with γ-Enolase and the Effects of Selective Cathepsin X Inhibitors.
Majc B; Habič A; Novak M; Rotter A; Porčnik A; Mlakar J; Župunski V; Pečar Fonović U; Knez D; Zidar N; Gobec S; Kos J; Lah Turnšek T; Pišlar A; Breznik B
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163706
[TBL] [Abstract][Full Text] [Related]
35. Facile synthesis of lactoferrin conjugated ultra small large pore silica nanoparticles for the treatment of glioblastoma.
Janjua TI; Ahmed-Cox A; Meka AK; Mansfeld FM; Forgham H; Ignacio RMC; Cao Y; McCarroll JA; Mazzieri R; Kavallaris M; Popat A
Nanoscale; 2021 Oct; 13(40):16909-16922. PubMed ID: 34533167
[TBL] [Abstract][Full Text] [Related]
36. Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study.
Ali S; Borin TF; Piranlioglu R; Ara R; Lebedyeva I; Angara K; Achyut BR; Arbab AS; Rashid MH
PLoS One; 2021; 16(2):e0246646. PubMed ID: 33544755
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological targeting of the tumor-immune symbiosis in glioblastoma.
Pang L; Khan F; Dunterman M; Chen P
Trends Pharmacol Sci; 2022 Aug; 43(8):686-700. PubMed ID: 35534356
[TBL] [Abstract][Full Text] [Related]
38. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells.
Kim JS; Shin DH; Kim JS
J Control Release; 2018 Jan; 269():245-257. PubMed ID: 29162480
[TBL] [Abstract][Full Text] [Related]
39. Multifunctional exosome-mimetics for targeted anti-glioblastoma therapy by manipulating protein corona.
Wu JY; Li YJ; Wang J; Hu XB; Huang S; Luo S; Xiang DX
J Nanobiotechnology; 2021 Dec; 19(1):405. PubMed ID: 34872569
[TBL] [Abstract][Full Text] [Related]
40. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model.
Mercurio L; Ajmone-Cat MA; Cecchetti S; Ricci A; Bozzuto G; Molinari A; Manni I; Pollo B; Scala S; Carpinelli G; Minghetti L
J Exp Clin Cancer Res; 2016 Mar; 35():55. PubMed ID: 27015814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
